Logo

PharmaShots Weekly Snapshots (August 1 – 5, 2022)

Share this
PharmaShots Weekly Snapshots (August 1 – 5, 2022)

PharmaShots Weekly Snapshots (August 1 – 5, 2022)

Pfizer to Discontinue P-III (REALM-DCM) Trial of PF-07265803 for the Treatment of LMNA-Related Dilated Cardiomyopathy

Published: Aug 5, 2022 | Tags: Pfizer, PF-07265803, LMNA-Related Dilated Cardiomyopathy, Clinical Trial, P-III, REALM-DCM Trial

AstraZeneca Entered into a Two-Year Collaboration with Thorne HealthTech for Disease Discovery System to Advance Novel Product Development

Published: Aug 5, 2022 | Tags: AstraZeneca, Thorne HealthTech, Disease Discovery System, Pharma, multi-omic platform, AI model

Innovent Entered into a Collaboration and License Agreement with Sanofi to Advance Development of Therapies for Cancer in China

Published: Aug 5, 2022 | Tags: Innovent Sanofi, Cancer, SAR408701, SAR444245, Pharma, China

Scynexis Presents P-III (CANDLE) Study Results of Ibrexafungerp for the Prevention of Recurrent Vaginal Yeast Infections at IDSOG 2022

Published: Aug 5, 2022 | Tags: Scynexis, Ibrexafungerp, Recurrent Vaginal Yeast Infections, Clinical Trial, P-III (CANDLE) Study, IDSOG, 2022

Grünenthal Entered into a License Agreement with Shionogi for Resiniferatoxin (RTX) to Treat Pain Associated with Knee Osteoarthritis

Published: Aug 5, 2022 | Tags: Grünenthal, Shionogi, Resiniferatoxin, RTX, Knee Osteoarthritis, Pharma

Amgen to Acquire Chemocentryx for ~$4B

Published: Aug 5, 2022 | Tags: Amgen, Chemocentryx, Tavneos, Otezla, Enbrel, Tezspire, Amgevita, Riabni & Avsola Autoimmune Diseases, Inflammatory Disorders, Cancer, Acquire, ~$4B

Alnylam Reports P-III (APOLLO-B) Trial Results of Patisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Published: Aug 4, 2022 | Tags: Alnylam, Patisiran, ATTR Amyloidosis, Cardiomyopathy, Clinical Trial, P-III APOLLO-B Trial

AstraZeneca and MSD’s Lynparza (olaparib) Receive EC’s Approval as Adjuvant Treatment for Germline BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer

Published: Aug 4, 2022 | Tags: AstraZeneca, MSD, Lynparza, Olaparib, Germline BRCA-Mutated, Breast Cancer, Regulatory, EC, Approval

Radiopharm Entered into an Agreement with Lantheus for the Development of NM-01

Published: Aug 4, 2022 | Tags: Radiopharm, Lantheus, NanoMab, NM-01, Non-Small Cell Lung Cancer, Pharma

Sumitomo Pharma Oncology’s DSP-5336 Receives the US FDA’s Orphan Drug Designation for the Treatment of Acute Myeloid Leukemia

Published: Aug 4, 2022 | Tags: Sumitomo Pharma Oncology, DSP-5336, Acute Myeloid Leukemia, Regulatory, US, FDA, Orphan Drug Designation

Poseida Entered into a Collaboration and License Agreement with Roche for Allogeneic CAR-T Cell Therapies to Treat Hematologic Malignancies

Published: Aug 4, 2022 | Tags: Poseida, Roche, Allogeneic CAR-T Cell Therapies, BCMA-ALLO1, P-CD19CD20-ALLO1, P-BCMACD19-ALLO1, P-CD70-ALLO1, Hematologic Malignancies, Biotech

Kiniksa Entered into a Global License Agreement with Genentech to Develop and Commercialize Vixarelimab for Fibrosis

Published: Aug 4, 2022 | Tags: Kiniksa, Genentech, Vixarelimab, Fibrosis, Prurigo Nodularis, Pharma

AbCellera Collaborated with Atlas Venture to Discover Therapeutic Antibodies Against Three Drug Targets

Published: Aug 3, 2022 | Tags: AbCellera, Atlas Venture, Therapeutic Antibodies, Biotech

Merck and Eisai Provide P-III (LEAP-002) Trial Update of Keytruda (pembrolizumab) + Lenvima (lenvatinib) for Unresectable Hepatocellular Carcinoma

Published: Aug 3, 2022 | Tags: Merck, Eisai, Keytruda, pembrolizumab, Lenvima, Lenvatinib, Hepatocellular Carcinoma, Clinical Trial, P-III LEAP-002 Trial

Context and Menarini Entered into a Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR + Elacestrant for Metastatic Breast Cancer

Published: Aug 3, 2022 | Tags: Context, Menarini, ONA-XR, Elacestrant, Metastatic Breast Cancer, Pharma

TransCode Collaborated with MD Anderson to Advance RNA Therapies for the Treatment of Cancer

Published: Aug 3, 2022 | Tags: TransCode, MD Anderson, RNA Therapies, Oncology, Biotech

Coherus’ Cimerli (biosimilar, ranibizumab) Receives the US FDA’s Approval as a First Interchangeable Biosimilar for the Treatment of Retinal Disease

Published: Aug 3, 2022 | Tags: Coherus, Cimerli, biosimilar, ranibizumab, Retinal Disease, Regulatory, Interchangeable Biosimilar, US, FDA, Approval

Rigel Entered into an Exclusive WW License Agreement with Forma to Develop and Commercialize Olutasidenib for Acute Myeloid Leukemia

Published: Aug 2, 2022 | Tags: Rigel, Forma, Olutasidenib, Acute Myeloid Leukemia, Pharma

Caris Life Sciences Entered into a Multi-Year Strategic Option and License Agreement with Xencor for Novel XmAb Bispecific Antibodies to Treat Cancer

Published: Aug 2, 2022 | Tags: Caris Life Sciences, Xencor, Novel XmAb Bispecific Antibodies, Cancer, Biotech, XmAb Engineering Platform

Roche Reports P-III (IMscin001) Study Results of Subcutaneous Formulation of Tecentriq for the Treatment of Non-Small Cell Lung Cancer

Published: Aug 2, 2022 | Tags: Roche, Tecentriq, Non-Small Cell Lung Cancer, Clinical Trial, P-III IMscin001 Study

Nyxoah Entered into a Distribution Agreement with Acurable for AcuPebble SA100 Home Sleep Test to Treat Obstructive Sleep Apnea in Germany

Published: Aug 2, 2022 | Tags: Nyxoah, Acurable, AcuPebble SA100 Home Sleep Test, Obstructive Sleep Apnea, Medtech, Germany

Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for the Treatment of Active Psoriatic Arthritis in Pediatric Patients

Published: Aug 2, 2022 | Tags: Janssen, Stelara, ustekinumab, Active Psoriatic Arthritis, Regulatory, US, FDA, Approval, STELARA withMe Support Program

Avalo Entered into an Exclusive WW License Agreement with Apollo to Develop and Commercialize AVTX-007 (camoteskimab) for Non-Eosinophilic Asthma

Published: Aug 2, 2022 | Tags: Avalo, Apollo, AVTX-007, camoteskimab, Non-Eosinophilic Asthma, Pharma, P-II (PEAK) Trial

Sosei Heptares Entered into a Research Collaboration and Option to License Agreement with AbbVie for Novel Therapies to Treat Neurological Diseases

Published: Aug 1, 2022 | Tags: Sosei Heptares, AbbVie, Novel Therapies, Neurological Diseases, Pharma, Heptares’ StaR Technology, SBDD Platform, GPCR Targets

Arecor to Acquire Tetris Pharma for Ogluo

Published: Aug 1, 2022 | Tags: Arecor, Tetris Pharma, Ogluo, Gvoke PFS, Gvoke HypoPen, Hypoglycaemia, Diabetes, M&A, Acquire

HUTCHMED Reports the Initiation of Tazemetostat in Bridging Study for the Treatment of Follicular Lymphoma in China

Published: Aug 1, 2022 | Tags: HUTCHMED, Tazemetostat, Follicular Lymphoma, Clinical Trial, Bridging Study, China

Arcutis’ Zoryve (roflumilast) Receives the US FDA's NDA Approval for Plaque Psoriasis in Individuals Aged ≥12 Years

Published: Aug 1, 2022 | Tags: Arcutis, Zoryve, roflumilast, Plaque Psoriasis, Regulatory, US, FDA, NDA, Approval

Novo Nordisk Reports P-IIIa (ONWARDS 3 & 4) Trials Results of Insulin Icodec for the Treatment of Type 2 Diabetes

Published: Aug 1, 2022 | Tags: Novo Nordisk, Insulin Icodec, Type 2 Diabetes, P-IIIa, ONWARDS 3 & 4 Trials, Clinical Trial, Type 2 Diabetes

ViiV Healthcare Presents Five-Year P-III (BRIGHTE) Study Results of Fostemsavir for Multidrug-Resistant HIV-1 Infection at AIDS 2022

Published: Aug 1, 2022 | Tags: ViiV Healthcare, Fostemsavir, Multidrug-Resistant, HIV-1 Infection, Clinical Trial, P-III BRIGHTE Study, AIDS 2022

Ipsen Collaborated with Marengo Therapeutics to Advance Two Precision Immuno-Oncology Therapies Using STAR Platform

Published: Aug 1, 2022 | Tags:  Ipsen, Marengo Therapeutics, Precision Immuno-Oncology Therapies, STAR Platform, Cancer, Pharma, TCR Vβ-Targeted Precision T Cell

Related Post: PharmaShots Weekly Snapshots (July 25 – 29, 2022)


Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions